nf κb inhibitor  (TargetMol)

Journal: European Journal of Medical Research

Article Title: PEAK1 promotes prostate cancer progression and docetaxel resistance by mediating the polarization of tumor-associated macrophages

doi: 10.1186/s40001-025-03568-2

Figure Lengend Snippet: Functions of PEAK1 on the HIF-1α/STAT3/NF-κB pathway activation in PCa cells. A WB was conducted to test the protein levels of HIF-1α, PD-L1, p -STAT3, and p –p65 in PC3 and DU145 cells with PEAK1 overexpression. B , C WB was conducted to test the protein levels of HIF-1α, PD-L1, p -STAT3, and p –p65 in PC3 and DU145 cells with PEAK1 knocking down. D WB was conducted to test the protein levels of HIF-1α, PD-L1, p -STAT3, and p –p65 in PC3 cells with PEAK1 overexpression and co-culturing with THP1 cells. E , F WB was conducted to test the protein levels of HIF-1α, PD-L1, p -STAT3, and p –p65 in PC3 and DU145 cells with PEAK1 overexpression and LW6, Stattic or Bay 11–7082 treatment. N = 3. * stands for p < 0.05, ** stands for p < 0.01, *** stands for p < 0.001

Article Snippet: The PC3 and DU145 cells were treated with the HIF-1α inhibitor LW6 (10 μM, #HY-13671, MedChemExpress) [ ]; the STAT3 inhibitor Stattic (10 μM, #HY-13818, MedChemExpress) [ ]; the NF-κB inhibitor Bay 11–7082 (15 μM, #HY-13453, MedChemExpress) [ ]; and increasing doses of enzalutamide (5 μM, 10 μM, 20 μM, and 40 μM, #HY-70002, MedChemExpress) [ ] for 24 h.

Techniques: Activation Assay, Over Expression

Journal: European Journal of Medical Research

Article Title: PEAK1 promotes prostate cancer progression and docetaxel resistance by mediating the polarization of tumor-associated macrophages

doi: 10.1186/s40001-025-03568-2

Figure Lengend Snippet: Mechanistic diagram of PEAK1 in PCa. Summary diagram of the functions and mechanisms of PEAK1 in PCa. Upregulated PEAK1 promotes the HIF-1α/STAT3/NF-κB pathway activation, thus enhancing tumor proliferation, migration, EMT, and reducing apoptosis, docetaxel/enzalutamide sensitivity. PEAK1 enhances CCL2, IL-6 and PD-L1 expression from PCa cells, which mediate “M2” polarization of TAMs and inducing TGF- β expression from TAMs. TGF- β can act on PCa cells and induce PEAK1 upregulation

Article Snippet: The PC3 and DU145 cells were treated with the HIF-1α inhibitor LW6 (10 μM, #HY-13671, MedChemExpress) [ ]; the STAT3 inhibitor Stattic (10 μM, #HY-13818, MedChemExpress) [ ]; the NF-κB inhibitor Bay 11–7082 (15 μM, #HY-13453, MedChemExpress) [ ]; and increasing doses of enzalutamide (5 μM, 10 μM, 20 μM, and 40 μM, #HY-70002, MedChemExpress) [ ] for 24 h.

Techniques: Activation Assay, Migration, Expressing